Search Results for "amyloidosis"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Comparison of Efficacy Outcomes with Vutrisiran vs. Patisiran in hATTR Amyloidosis with Polyneuropathy: Post-hoc Analysis of the HELIOS-A Study

Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis

Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation

Patisiran: Technetium Uptake by Scintigraphy

Standard response letter on patisiran and technetium scintigraphy data assessed in a subset of patients from the APOLLO-B study.

Musculoskeletal manifestations in patients with ATTR amyloidosis: Evidence from real-world analyses and clinical trials

HELIOS A: Study of Vutrisiran in Patients with hATTR Amyloidosis

Exploratory Analyses from APOLLO-B, A Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

HELIOS-A: 9-Month Results from the Randomized Treatment Extension Period of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Impact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.